Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q1 2021 Earnings Presentation
14 slides from Adc Therapeutics Sa's earnings presentation, May 6, 2021
Slide 1: Innovating Science. Inspiring Hope. 1Q 2021 Results
Innovating Science. Inspiring Hope. 1Q 2021 Results May 6, 2021
Slide 2: Agenda
Agenda 01 Chris Martin Introduction Chief Executive Officer Jennifer Herron Commercial Highlights 02 Chief Commercial Officer Jay Feingold Clinical Highlights 03 Chief Medical Officer Jenn Creel Financial Update 04 Chief Financial Officer 2
Slide 3: Forward-looking statements
Forward-looking statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 4: Accelerated Approval of ZYNLONTA Granted by the FDA
Accelerated Approval of ZYNLONTA Granted by the FDA ZYNLONTATM (loncastuximab tesirine-lpyl) is indicated for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not other
Slide 5: Recent Highlights
Recent Highlights ZYNLONTATM (loncastuximab tesirine-lpyl) § FDA accelerated approval granted on April 23, 2021 for the treatment of patients with r/r DLBCL, followed by immediate launch § NCCN guideline Category 2A recommendation for third-line plus DLBCL, including DLBCL arising from low-grade lym
Slide 6: ZYNLONTA Websites and Digital Platforms Launched
ZYNLONTA Websites and Digital Platforms Launched 6
Slide 7: ZYNLONTA Launch in Full Swing
CORPORATE ZYNLONTA Launch in Full Swing World-class Account team of directors and Orders seasoned MSLs actively received and oncology engaged with professionals key payor product with strong shipped stakeholders local networks within days of approval Comprehensive patient Commercial Well-prepared as
Slide 8: ZYNLONTA addresses unmet need in 3L+ DLBCL market
CORPORATE ZYNLONTA addresses unmet need in 3L+ DLBCL market Significant Unmet Need in r/r DLBCL § 3L+ r/ r DLBCL includes heavily pretreated patients with difficult to treat disease, including patients who: - Did not respond to first-line or any prior line of therapy - Failed CAR T therapy or stem c
Slide 9: Expanding the Potential for ZYNLONTA
Expanding the Potential for ZYNLONTA Additional trials in 2021 § Pivotal Ph 2 trial in FL LOTIS-5 § Dose-finding study of ZYNLONTA in combination ZYNLONTA with R-CHOP in 1L DLBCL + rituximab § ZYNLONTA in multiple combinations in NHL § Ph 3 trial in combination with rituximab LOTIS-3 § Intended to s
Slide 10: Cami Clinical Programs Advancing
Cami Clinical Programs Advancing Novel ADC targeting CD25 and regulatory T cells (Tregs) Relapsed or refractory Hodgkin lymphoma Advanced solid tumors § Phase 2 pivotal trial ongoing; enrollment § Phase 1b trial of Cami + pembrolizumab complete ongoing § Data presented at ASH 2020 demonstrating § Ca
Slide 11: Leveraging Validated ADC Platform in Solid Tumor Franchise
Leveraging Validated ADC Platform in Solid Tumor Franchise Cami ADCT-901 ADCT-601 Targeting CD25 Targeting KAAG-1 Targeting AXL § Dose-escalation of Phase 1b § Targeting advanced solid § AXL overexpressed in many trial ongoing tumors with high unmet solid tumors - lung, breast, § Targeting advanced
Slide 12: 1Q 2021 Financial Update (in $ millions)
1Q 2021 Financial Update (in $ millions) Balance Sheet March 31, 2021 December 31, 2020 Cash and cash equivalents $383.1 $439.2 Statement of Cash Flows Q1 2021 Net cash used for operating activities $55.1 3 Months Ended Statement of Operations March 31 2021 2020 Research & Development Expenses $39.2
Slide 13: Anticipated Development Milestones
Anticipated Development Milestones ZYNLONTA § 2Q 2021: § Initiate pivotal Phase 2 trial in FL § Updated Phase 1 data from ZYNLONTA combo trial with ibrutinib in r/r DLBCL § 2H 2021: § Initiate first line dosing trial of ZYNLONTA with R-CHOP § Complete enrollment in pivotal Phase 2 trial of ZYNLONTA
Slide 14: Innovating Science. Inspiring Hope.
Innovating Science. Inspiring Hope. 1Q 2021 Results